|
1
|
Lei Z, Duan H, Zhao T, Zhang Y, Li G, Meng
J, Zhang S and Yan W: PARK2 inhibits osteosarcoma cell growth
through the JAK2/STAT3/VEGF signaling pathway. Cell Death Dis.
9:3752018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morrow JJ and Khanna C: Osteosarcoma
genetics and epigenetics: Emerging biology and candidate therapies.
Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Na KY, Bacchini P, Bertoni F, Kim YW and
Park YK: Syndecan-4 and fibronectin in osteosarcoma. Pathology.
44:325–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lilic V, Lilic G, Filipovic S, Milosevic
J, Tasic M and Stojiljkovic M: Modern treatment of invasive
carcinoma of the uterine cervix. J BUON. 14:587–592. 2009.
|
|
5
|
Carnelio S, Pai K, Rao N, Solomon M and
Ahasan A: Metastatic osteosarcoma to the maxilla: A case report and
a review of the literature. Quintessence Int. 33:397–399.
2002.PubMed/NCBI
|
|
6
|
Bonnon C and Atanasoski S: c-Ski in health
and disease. Cell Tissue Res. 347:51–64. 2012. View Article : Google Scholar
|
|
7
|
Li Y, Turck CM, Teumer JK and Stavnezer E:
Unique sequence, ski, in sloankettering avian retroviruses with
properties of a new cell-derived oncogene. J Virol. 57:1065–1072.
1986.PubMed/NCBI
|
|
8
|
Luo K, Stroschein SL, Wang W, Chen D,
Martens E, Zhou S and Zhou Q: The Ski oncoprotein interacts with
the Smad proteins to repress TGFbeta signaling. Genes Dev.
13:2196–2206. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Villanacci V, Bellone G, Battaglia E,
Rossi E, Carbone A, Prati A, Verna C, Niola P, Morelli A, Grassini
M and Bassotti G: Ski/SnoN expression in the sequence
metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Hum
Pathol. 39:403–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buess M, Terracciano L, Reuter J,
Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R and
Rochlitz C: Amplification of SKI is a prognostic marker in early
colorectal cancer. Neoplasia. 6:207–212. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakao T, Kurita N, Komatsu M, Yoshikawa K,
Iwata T, Utsunomiya T and Shimada M: Expression of thrombospondin-1
and Ski are prognostic factors in advanced gastric cancer. Int J
Clin Oncol. 16:145–152. 2011. View Article : Google Scholar
|
|
12
|
Heider TR, Lyman S, Schoonhoven R and
Behrns KE: Ski promotes tumor growth through abrogation of
transforming growth factor-beta signaling in pancreatic cancer. Ann
Surg. 246:61–68. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen D, Lin Q, Box N, Roop D, Ishii S,
Matsuzaki K, Fan T, Hornyak TJ, Reed JA, Stavnezer E, et al: SKI
knockdown inhibits human melanoma tumor growth in vivo. Pigment
Cell Melanoma Res. 22:761–772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fumagalli S, Doneda L, Nomura N and
Larizza L: Expression of the c-ski proto-oncogene in human melanoma
cell lines. Melanoma Res. 3:23–27. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao X, Zhou KS, Li ZH, Nan W, Wang J, Xia
YY and Zhang HH: Knockdown of Ski decreased the reactive astrocytes
proliferation in vitro induced by oxygen-glucose
deprivation/reoxygenation. J Cell Biochem. 119:4548–4558. 2018.
View Article : Google Scholar
|
|
16
|
Zhao X, Wang XW, Zhou KS, Nan W, Guo YQ,
Kou JL, Wang J, Xia YY and Zhang HH: Expression of Ski and its role
in astro-cyte proliferation and migration. Neuroscience. 362:1–12.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Sun X, Bao Y, Mo J, Du H, Hu J and
Zhang X: E2F1 silencing inhibits migration and invasion of
osteosarcoma cells via regulating DDR1 expression. Int J Oncol.
51:1639–1650. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang W, Yu Y, Liu J, Zhao Q, Wang J,
Zhang J and Dang X: Downregulation of Cdc6 inhibits tumorigenesis
of osteosarcoma in vivo and in vitro. Biomed Pharmacother.
115:1089492019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen R, Huang LH, Gao YY, Yang JZ and Wang
Y: Identification of differentially expressed genes in MG63
osteosarcoma cells with drug-resistance by microarray analysis. Mol
Med Rep. 19:1571–1580. 2019.
|
|
20
|
Chen R, Wang G, Zheng Y, Hua Y and Cai Z:
Drug resistance-related microRNAs in osteosarcoma: Translating
basic evidence into therapeutic strategies. J Cell Mol Med.
23:2280–2292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kokura K, Kim H, Shinagawa T, Khan MM,
Nomura T and Ishii S: The Ski-binding protein C184M negatively
regulates tumor growth factor-beta signaling by sequestering the
Smad proteins in the cytoplasm. J Biol Chem. 278:20133–20139. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li J, Li P, Zhang Y, Li GB, Zhou YG, Yang
K and Dai SS: c-Ski inhibits the proliferation of vascular smooth
muscle cells via suppressing Smad3 signaling but stimulating p38
pathway. Cell Signal. 25:159–167. 2013. View Article : Google Scholar
|
|
23
|
Li J, Zhao L, He X, Yang T and Yang K:
MiR-21 inhibits c-Ski signaling to promote the proliferation of rat
vascular smooth muscle cells. Cell Signal. 26:724–729. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Colmenares C and Stavnezer E: The ski
oncogene induces muscle differentiation in quail embryo cells.
Cell. 59:293–303. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H and Stavnezer E: Ski regulates
muscle terminal differentiation by transcriptional activation of
Myog in a complex with Six1 and Eya3. J Biol Chem. 284:2867–2879.
2009. View Article : Google Scholar :
|
|
26
|
Macias-Silva M, Li W, Leu JI, Crissey MA
and Taub R: Up-regulated transcriptional repressors SnoN and Ski
bind Smad proteins to antagonize transforming growth factor-beta
signals during liver regeneration. J Biol Chem. 277:28483–28490.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Hou Y, Sun Y, Zhao L, Tang X, Hu
P, Yang J, Zeng Z, Yang G, Cui X and Liu M: c-Ski activates
cancer-associated fibroblasts to regulate breast cancer cell
invasion. Mol Oncol. 7:1116–1128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reed JA, Lin Q, Chen D, Mian IS and
Medrano EE: SKI pathways inducing progression of human melanoma.
Cancer Metastasis Rev. 24:265–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang P, Chen Z, Meng ZQ, Fan J, Luo JM,
Liang W, Lin JH, Zhou ZH, Chen H, Wang K, et al: Dual role of Ski
in pancreatic cancer cells: Tumor-promoting versus
metastasis-suppressive function. Carcinogenesis. 30:1497–1506.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Atanasoski S, Notterpek L, Lee HY,
Castagner F, Young P, Ehrengruber MU, Meijer D, Sommer L, Stavnezer
E, Colmenares C and Suter U: The protooncogene Ski controls schwann
cell proliferation and myelination. Neuron. 43:499–511. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang J, Dey R, Wang Y, Jakoncic J,
Kurinov I and Huang XY: Structural insights into the induced-fit
inhibition of fascin by a small-molecule inhibitor. J Mol Biol.
430:1324–1335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao LL, Pei XF, Qiao X, Yu J, Ye H, Xi CL,
Wang PY and Gong ZL: SERPINA3 silencing inhibits the migration,
invasion, and liver metastasis of colon cancer cells. Dig Dis Sci.
63:2309–2319. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Oliveira Poswar F, de Carvalho Fraga
CA, Gomes ES, Farias LC, Souza LW, Santos SH, Gomez RS, de-Paula AM
and Guimarães AL: Protein expression of MMP-2 and MT1-MMP in
actinic keratosis, squamous cell carcinoma of the skin, and basal
cell carcinoma. Int J Surg Pathol. 23:20–25. 2015. View Article : Google Scholar
|
|
34
|
Qin H, Liu X, Li F, Miao L, Li T, Xu B, An
X, Muth A, Thompson PR, Coonrod SA and Zhang X: PAD1 promotes
epithelial-mesenchymal transition and metastasis in triple-negative
breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
Cancer Lett. 409:30–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Zhu SC, Li SG, Zhao Y, Xu JR and
Song CY: TKTL1 promotes cell proliferation and metastasis in
esophageal squamous cell carcinoma. Biomed Pharmacother. 74:71–76.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Arndt S, Schmidt J, Wacker E, Karrer S and
Bosserhoff AK: Fussel-15, a new player in wound healing, is
deregulated in keloid and localized scleroderma. Am J Pathol.
178:2622–2631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brader S and Eccles SA: Phosphoinositide
3-kinase signalling pathways in tumor progression, invasion and
angiogenesis. Tumori. 90:2–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cohen-Solal KA, Boregowda RK and Lasfar A:
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving
force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gu QZ, Nijiati A, Gao X, Tao KL, Li CD,
Fan XP and Tian Z: TROP2 promotes cell proliferation and migration
in osteosarcoma through PI3K/AKT signaling. Mol Med Rep.
18:1782–1788. 2018.PubMed/NCBI
|
|
41
|
Zhang Y, Cheng H, Li W, Wu H and Yang Y:
Highly-expressed P2X7 receptor promotes growth and metastasis of
human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and
mTOR/HIF1α/VEGF signaling. Int J Cancer. 145:1068–1082. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma J, Huang H, Han Z, Zhu C and Yue B:
RLN2 is a positive regulator of Akt-2-induced gene expression
required for osteosarcoma cells invasion and chemoresistance.
Biomed Res Int. 2015:1474682015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang H, Luo QF, Peng AF, Long XH, Wang TF,
Liu ZL, Zhang GM, Zhou RP, Gao S, Zhou Y and Chen WZ: Positive
feedback regulation between Akt phosphorylation and fatty acid
synthase expression in osteosarcoma. Int J Mol Med. 33:633–639.
2014. View Article : Google Scholar
|
|
44
|
Liu T, Zhou W, Cai B, Chu J, Shi G, Teng
H, Xu J, Xiao J and Wang Y: IRX2-mediated upregulation of MMP-9 and
VEGF in a PI3K/AKT-dependent manner. Mol Med Rep. 12:4346–4351.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Long XH, Zhong ZH, Peng AF, Zhu LB, Wang
H, Zhang GM and Liu ZL: LY294002 suppresses the malignant phenotype
and sensitizes osteosarcoma cells to pirarubicin chemotherapy. Mol
Med Rep. 10:2967–2972. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou Y, Zhu LB, Peng AF, Wang TF, Long XH,
Gao S, Zhou RP and Liu ZL: LY294002 inhibits the malignant
phenotype of osteosarcoma cells by modulating the
phosphatidylinositol 3-kinase/Akt/fatty acid synthase signaling
pathway in vitro. Mol Med Rep. 11:1352–1357. 2015. View Article : Google Scholar
|
|
47
|
Jiang F, Zhang D, Li G and Wang X:
Knockdown of DDX46 inhibits the invasion and tumorigenesis in
osteosarcoma cells. Oncol Res. 25:417–425. 2017. View Article : Google Scholar
|
|
48
|
Chen J, Liu C, Yang QQ, Ma RB, Ke Y, Dong
F and Wu XE: Isoliquiritigenin suppresses osteosarcoma U2OS cell
proliferation and invasion by regulating the PI3K/Akt signalling
pathway. Chemotherapy. 63:155–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Band AM, Björklund M and Laiho M: The
phosphatidylinositol 3-kinase/Akt pathway regulates transforming
growth factor-{beta} signaling by destabilizing ski and inducing
Smad7. J Biol Chem. 284:35441–35449. 2009. View Article : Google Scholar : PubMed/NCBI
|
